JNJ

In the Large-Cap Pharmaceuticals industry, LLY, J&J and BAYRY are worth watching as the industry shows a strong recovery.

Dividend Kings, companies with at least 50 consecutive years of dividend increases, remain the backbone of any buy-and-hold income portfolio.

Johnson & Johnson (NYSE:JNJ | JNJ Price Prediction) and AbbVie (NYSE:ABBV) both delivered strong quarters, but they tell very different dividend stories.

The iShares Core High Dividend ETF (NYSEARCA:HDV) leans hard on two sectors to fund its payout.

At $261.81, Johnson & Johnson (NYSE:JNJ | JNJ Price Prediction) is a hold.

J&J's growth, new drug launches and pipeline strength support the stock, despite patent, MedTech and legal headwinds.

Year to date, the healthcare sector finds itself in the middle of the S&P 500's pack.

Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Johnson & Johnson (JNJ) have what it takes?

Volatility has been the theme of 2026. The VIX touched 31.05 in late March before settling back to a current reading of 15.86, and the 10-year Treasury yield sits at 4.70%, near the top of its 12-month range.

Retirement portfolios in August 2026 face a specific puzzle. Bond yields have come off their highs, equity valuations remain elevated, and the biggest secular story in markets, AI infrastructure, is dominated by expensive growth names that pay little or nothing in income.